MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329515 | Name: Tulrampator
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tulrampator, also known as S-47445 and CX-1632, is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by RespireRx Pharmaceuticals (formerly Cortex Pharmaceuticals) and Servier for the treatment of major depressive disorder (as an adjunct), Alzheimer's disease, dementia, and mild cognitive impairment.

Chemical Structure

Tulrampator
Tulrampator
CAS#1038984-31-4

Theoretical Analysis

MedKoo Cat#: 329515

Name: Tulrampator

CAS#: 1038984-31-4

Chemical Formula: C20H17FN4O3

Exact Mass: 380.1285

Molecular Weight: 380.38

Elemental Analysis: C, 63.15; H, 4.50; F, 4.99; N, 14.73; O, 12.62

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,150.00 Ready to ship
1g USD 3,450.00 Ready to ship
2g USD 6,450.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tulrampator; S-47445; S 47445; S47445; CX-1632; CX 1632; CX1632;
IUPAC/Chemical Name
8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione
InChi Key
JHCFQXNWYDLBOG-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H17FN4O3/c21-13-3-1-2-12(8-13)6-7-25-20(27)15-10-18-16(9-17(15)22-23-25)19(26)24(11-28-18)14-4-5-14/h1-3,8-10,14H,4-7,11H2
SMILES Code
O=C1N(CCC2=CC=CC(F)=C2)N=NC3=CC4=C(OCN(C5CC5)C4=O)C=C13
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Tulrampator is a "high-impact" AMPAR potentiator, unlike "low-impact" AMPAR potentiators like CX-516 and its congener farampator (CX-691, ORG-24448), and is able to elicit more robust increases in AMPAR activation. In animals, high-impact AMPAR potentiators enhance cognition and memory at low doses, but produce motor coordination disruptions, convulsions, and neurotoxicity at higher doses. Tulrampator itself has been found in animals to enhance cognition and memory, to produce antidepressant-, antianhedonic-, and anxiolytic-like effects, and to have neurotrophic and neuroplasticity-promoting activities. Moreover, it has been found to increase levels of brain-derived neurotrophic factor (BDNF) in the hippocampus and to stimulate hippocampal neurogenesis.
Biological target:
S 47445 is a positive AMPAR (allosteric modulator of AMPA receptor).
In vitro activity:
Aberrant or excessive activation of ionotropic glutamatergic receptors can result under some circumstances to cell death due to a phenomenon of excitotoxicity. To evaluate the potential neurotoxic effect of the compound in vitro, S 47445 was incubated in absence or in presence of glutamate on cultured rat primary cortical neurones. S 47445 was not toxic to rat primary cortical cell cultures up to 10 μM after 24 hrs exposure when applied alone (n = 4 independent cultures, Fig 9A). Furthermore, in contrast to what may be expected following a potentiation of AMPA receptors, S 47445 (0.1, 3 and 10 μM) also did not potentiate glutamate-mediated toxicity on rat primary cortical neuronal culture, whatever the concentration of glutamate used (n = 4 independent cultures, Fig 9B). Instead, S 47445 at 10 μM elicited a significant protective effect against glutamate injury observed at 50, 75 and 100 μM by reducing glutamate-induced LDH (lactate deshydrogenase) activity by 32.2, 50.9 and 49.0% (Fig 9B). Reference: PLoS One. 2017 Sep 8;12(9):e0184429. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590943/
In vivo activity:
The mechanisms by which S 47445 could improve synaptic strength and connectivity were studied and compared between young and old mice. A single oral administration of S 47445 at 10 mg/kg significantly increased long-term potentiation (LTP) in CA3-CA1 hippocampal synapses in alert young mice in comparison to control mice. Moreover, chronic treatment with S 47445 at 10 mg/kg in old alert animals significantly counteracted the deficit of LTP due to age. Accordingly, chronic treatment with S 47445 at 10 mg/kg seems to preserve synaptic cytoarchitecture in old mice as compared with young control mice. It was shown that the significant decreases in number and size of pre-synaptic buttons stained for VGlut1, and post-synaptic dendritic spines stained for spinophilin, observed in old mice were significantly prevented after chronic treatment with 10 mg/kg of S 47445. By its different effects on LTP, VGlut1-positive particles, and spinophilin, S 47445 is able to modulate both the structure and function of hippocampal excitatory synapses known to be involved in learning and memory processes. Reference: Neuropharmacology. 2017 Sep 1;123:395-409. https://www.sciencedirect.com/science/article/pii/S0028390817302794?via%3Dihub
Solvent mg/mL mM
Solubility
DMSO 21.7 56.97
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 380.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Bretin S, Louis C, Seguin L, Wagner S, Thomas JY, Challal S, Rogez N, Albinet K, Iop F, Villain N, Bertrand S, Krazem A, Bérachochéa D, Billiald S, Tordjman C, Cordi A, Bertrand D, Lestage P, Danober L. Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors. PLoS One. 2017 Sep 8;12(9):e0184429. doi: 10.1371/journal.pone.0184429. PMID: 28886144; PMCID: PMC5590943. 2. Pilar-Cuellar F, Castro E, Bretin S, Mocaer E, Pazos Á, Díaz Á. S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:205-213. doi: 10.1016/j.pnpbp.2019.04.005. Epub 2019 Apr 10. PMID: 30980840. 3. Giralt A, Gómez-Climent MÁ, Alcalá R, Bretin S, Bertrand D, María Delgado-García J, Pérez-Navarro E, Alberch J, Gruart A. The AMPA receptor positive allosteric modulator S 47445 rescues in vivo CA3-CA1 long-term potentiation and structural synaptic changes in old mice. Neuropharmacology. 2017 Sep 1;123:395-409. doi: 10.1016/j.neuropharm.2017.06.009. Epub 2017 Jun 8. PMID: 28603025.
In vitro protocol:
1. Bretin S, Louis C, Seguin L, Wagner S, Thomas JY, Challal S, Rogez N, Albinet K, Iop F, Villain N, Bertrand S, Krazem A, Bérachochéa D, Billiald S, Tordjman C, Cordi A, Bertrand D, Lestage P, Danober L. Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors. PLoS One. 2017 Sep 8;12(9):e0184429. doi: 10.1371/journal.pone.0184429. PMID: 28886144; PMCID: PMC5590943.
In vivo protocol:
1. Pilar-Cuellar F, Castro E, Bretin S, Mocaer E, Pazos Á, Díaz Á. S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:205-213. doi: 10.1016/j.pnpbp.2019.04.005. Epub 2019 Apr 10. PMID: 30980840. 2. Giralt A, Gómez-Climent MÁ, Alcalá R, Bretin S, Bertrand D, María Delgado-García J, Pérez-Navarro E, Alberch J, Gruart A. The AMPA receptor positive allosteric modulator S 47445 rescues in vivo CA3-CA1 long-term potentiation and structural synaptic changes in old mice. Neuropharmacology. 2017 Sep 1;123:395-409. doi: 10.1016/j.neuropharm.2017.06.009. Epub 2017 Jun 8. PMID: 28603025.
1: Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019 Feb;24(2):606-615. doi: 10.1016/j.drudis.2018.11.007. Epub 2018 Nov 14. PMID: 30447328; PMCID: PMC6397075.